Singapore markets close in 2 hours 31 minutes
Straits Times Index
3,190.74 +36.05 (+1.14%) Nikkei
38,079.70 +117.90 (+0.31%) Hang Seng
16,441.12 +189.28 (+1.16%) FTSE 100
7,847.99 +27.63 (+0.35%) Bitcoin USD
61,146.27 -2,703.27 (-4.23%) CMC Crypto 200
885.54 0.00 (0.00%)
AZN Jan 2025 27.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:47PM EDT. Market open.
| Previous close | 40.60 |
| Open | 40.60 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 27.50 |
| Expiry date | 2025-01-17 |
| Day's range | 40.60 - 40.60 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
ZacksAstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
ZacksPharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
© 2024 Yahoo. All rights reserved.